Founded by seasoned entrepreneurs

PreComb Therapeutics AG was founded in 2018 by two experienced serial Entrepreneurs. Their accumulated and complementory expertises range from cell culture technology, product development, data management, biopharmaceutical development & production and clinical trial supply. From their past leadership roles in InSphero AG and ESBATech, both founders bring in a wealth of experices in technology development, personnel development, company build-up and maturation.

Founders at a glance

  • More than 40 years in biotech and pharma
  • 3 biotech companies founded
  • 15 years of expertise in 3D tissue models
  • >50 publications & 9 patents published
  • Process development of BEOVU®
  • Strong expertise in lab-automation, data science and AI
Jens Kelm, CEO

Jens M. Kelm, PhD

Co-Founder & CEO

Jens M. Kelm is one of the pioneers and initial developers of 3D tissue culture technology. He was founder, president and CSO of InSphero AG, commercializing physiological 3D models, assays and screening concepts. He is a co-founder of the Swiss competence center for 3D cell culture technologies (TEDD) and member of the steering committee of the 3D cell culture conference series 3DCC organized by the DECHEMA. Jens has published more than 50 publications and 11 Patents in the field. He holds a PhD in Biotechnology from the ETH Zürich.

Peter Steiner, PhD

Co-founder, COO and president of the board​

Formerly, Executive Director and Head of the Production & Processes department of ESBATech, a Novartis company. Responsible for manufacturing process development of BEOVU® (Brolucizumab, Novartis) and other drug candidates successfully tested in clinical POC trials. Co-founder and member of the board of Insilico Biotechnology AG. Peter holds a PhD in Biology (Biotechnology) from the ETH Zürich.

Peter Steiner, COO of PreComb

Olivier Mauti, PhD


Formerly Head of Lab automation at ESBATech and Novartis/NIBR – successfully built state-of-the-art screening facilities and data management systems for high throughput antibody screening. Olivier has strong expertise in data science, AI and laboratory automation. He holds PhD in Neurobiology and was working as PostDoc at Princeton University.

Patrick Aisher

Director / Board of Directors

Patrick is an Anglo-Austrian serial entrepreneur who has been active in early stage businesses since 1990. Throughout his career, he has created and invested in over fifty businesses, exiting twelve via IPO (in London, New York, and Madrid) and twelve via trade sale/licensing deal. Patrick is Chairman of Kinled Holding, a Hong Kong-based private investment company established in 1924, with offices in London, Shanghai, Vienna, and Zurich. Kinled holds a portfolio of more than 50 companies in the life sciences, digital and financial technology industries. He is a Director of Olipan Investments (TdT5) Inc. which specializes in later stage life science private equity investments, and and is a member of the Swiss Corporate Finance and Private Equity Association. A strong advocate of seed funding academic research into innovative business concepts, Patrick is also a Director of the Central European Biotechnology Incubator Accelerator in Vienna.

Patrick Aisher

Thomas Wegmann

Data Engineer

Thomas is an experienced software engineer and holds an MSc in Applied Computational Life Sciences. He is passionate about distributed systems, computer vision and building purposeful, easily maintainable software.

Kseniia Nikitina, PhD

Data Scientist

Kseniia is a trained Computer and Data Scientist with a deep fascination for finding patterns and structures in complex real-world data. She holds a PhD in Computer Science from the Technical University of Dresden.

Kseniia Kikitina